CytoDyn (STU:296) Non Operating Income: € Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:296 CytoDyn Inc STU:296
31 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is CytoDyn Non Operating Income?

CytoDyn STU:296 +0.58% 31 Non Operating Income is € Mil as of May. 2026. GuruFocus rates STU:296 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. CytoDyn's Non Operating Income for the three months ended in May. 2026 was € Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in May. 2026 was € Mil.

CytoDyn Non Operating Income Related Terms

CytoDyn Non Operating Income Historical Data

* Premium members only.

The historical data trend for CytoDyn's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Non Operating Income Chart

CytoDyn Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CytoDyn Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
STU:296
31GF Score
CytoDyn Inc STU:296
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was € Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of € Mil mean?
CytoDyn (STU:296) has a Non Operating Income of € Mil as of May. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on CytoDyn and its competitors.
Is CytoDyn's Non Operating Income too high?
CytoDyn's current Non Operating Income is € Mil. Overall, CytoDyn has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Non Operating Income compare to OBIO and IRD?
CytoDyn's Non Operating Income of € Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on CytoDyn and its competitors. CytoDyn's current Non Operating Income is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Non Operating Income of € Mil. The current Non Operating Income is € Mil. CytoDyn's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For CytoDyn (STU:296), the current Non Operating Income is € Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
31GF Score

Get the complete analysis for STU:296

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price